Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:NUWE

Nuwellis Q1 2026 Earnings Report

Nuwellis logo
$1.11 -0.01 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 +0.00 (+0.45%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nuwellis EPS Results

Actual EPS
N/A
Consensus EPS
-$1.00
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuwellis Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.09 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuwellis Announcement Details

Quarter
Q1 2026
Date
5/12/2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
9:00AM ET

Conference Call Resources

Nuwellis Earnings Headlines

Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026
May 5 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287585/26106/en/nuwellis-inc-to-announce-first-quarter-2026-financial-results-on-may-12-2026.html
Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283761/26106/en/nuwellis-highlights-case-study-featuring-precision-ultrafiltration-therapy-in-pediatric-cardiorenal-care-at-ishlt-2026-annual-meeting.html
Nobody Understands Why Trump Is Invading Iran (here’s the answer)
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.tc pixel
May 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282666/26106/en/nuwellis-announces-receipt-of-a-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-innovative-dual-lumen-midline-catheter-technology.html
Nuwellis Settles Lawsuit With E.F. Hutton, Resolving Dispute
April 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NUWE/pressreleases/1520663/nuwellis-settles-lawsuit-with-ef-hutton-resolving-dispute/
Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279911/26106/en/nuwellis-to-participate-in-the-aats-106th-annual-meeting-and-eras-cardiac-spring-retreat.html
See More Nuwellis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuwellis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuwellis and other key companies, straight to your email.

About Nuwellis

Nuwellis (NASDAQ:NUWE) (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting. This technology is used in hospitals, specialty renal centers and other acute care facilities. The system’s design emphasizes ease of use for clinicians, with automated control features and real‐time monitoring that support individualized treatment plans and help mitigate the risks associated with rapid fluid shifts.

Originally founded as Renal Solutions in 2005, the company adopted the Nuwellis name in 2016 to reflect a broader commitment to advancing fluid management therapies. Headquartered in Plymouth, Minnesota, Nuwellis holds both FDA clearance in the United States and CE Mark approval for distribution across Europe. Its sales and distribution network serves acute care hospitals and renal clinics across North America and select international markets.

Nuwellis continues to invest in research and development aimed at expanding the clinical applications of its ultrafiltration technology. The company’s leadership team includes seasoned executives with extensive experience in medical devices and healthcare innovation. Ongoing efforts focus on regulatory approvals, commercial partnerships and clinical studies to validate new indications and broaden access to its therapies worldwide.

View Nuwellis Profile
Earnings Tools